COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00790101
Recruitment Status : Terminated
First Posted : November 13, 2008
Last Update Posted : January 11, 2011
Information provided by:

Brief Summary:
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT.

Condition or disease Intervention/treatment Phase
Osteoporosis, Postmenopausal Drug: Risedronate Drug: Raloxifene Other: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: An 18-Month, Multicenter, Parallel-Group Study to Determine The Relative Efficacy of Risedronate Versus Raloxifene in Subjects Who Have Discontinued Hormone Replacement Therapy (HRT) for Early Intervention in Osteoporosis
Study Start Date : June 2004
Actual Study Completion Date : October 2004

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Risedronate 35mg once a week
Drug: Risedronate
Active Comparator: 2
Raloxifene 60mg daily
Drug: Raloxifene
Placebo Comparator: 3 Other: Placebo

Primary Outcome Measures :
  1. Compare the effects of risedronate and raloxifene on lumbar spine (LS) bone mineral density (BMD) in osteopenic women previously treated with HRT, who discontinued HRT at least 3 months prior to the study but no greater than 18 mos

Secondary Outcome Measures :
  1. Compare the effects of risedronate, raloxifene, and placebo on BMD of the hip

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Postmenopausal, ambulatory females, "postmenopausal" defined as the absence of menses for at least 12 continuous months)
  • In general good health as determined by medical history, physical examination, and laboratory tests
  • LS spine BMD T-score between -1.0 and -2.4, inclusive
  • At least one analyzable BMD site at both the hip (left or right) and LS spine (at least 3 measurable lumbar spine vertebrae, without fracture or sufficient degenerative disease)
  • Currently receiving no medications for the treatment or prevention of osteoporosis
  • Had been on continuous HRT for at least 1 year prior to enrollment. The HRT must have ended within 18 months prior to the baseline visit, and the subject must have been off HRT medication for at least 3 months at the time of baseline visit
  • Subjects rendered menopausal by surgical procedures between the ages of 55 and 65 years

Exclusion Criteria:

  • A history of cancer within 10 years prior to entry into the study, except for relatively "benign" and cured skin cancers such as basal and squamous cell carcinoma
  • A history of hyperparathyroidism, hyperthyroidism, osteomalacia, or other metabolic bone disease within one year prior to enrollment
  • Any condition or disease that may interfere with the evaluation of at least 3 lumbar vertebrae (not necessarily contiguous), determined in a screening radiograph by a radiologist at the central facility (e.g., confluent aortic calcifications, severe osteoarthritis, spinal fusion, lumbar spine fractures)
  • Evidence of clinically significant organic or psychiatric disease on history or physical examination, which in the opinion of the investigator would prevent the patient from completing the study
  • Markedly abnormal pretreatment laboratory finds that, in the opinion of the investigator, would prevent the patient from completing the study
  • A history of using any of the following medications prior to starting study:
  • Any bisphosphonate therapy
  • Selective estrogen receptor modulators (SERMs)
  • Parathyroid hormone
  • Fluorides
  • Calcitonin
  • Calcitriol (>1.5 mcg/week)
  • Corticosteroids on a chronic basis for period equal to or greater then 3 months
  • Received a depot injection of >10,000 IU Vitamin D in the past 12 months
  • A history of recurrent nephrolithiasis or a history of one episode of nephrolithiasis within 1 year of study entry
  • Serum creatinine >1.6 mg/dl
  • Unable to sit or stand upright for 30 minutes after taking the morning dose of risedronate
  • A history of deep vein thrombosis or other coagulation disorders
  • Severe hepatic insufficiency
  • A history of hypersensitivity to raloxifene, risedronate, or to drugs with similar chemical structures
  • Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
  • Subjects found to have one or more vertebral fractures after completing thoracic and LS spine films
  • Subjects who have experienced a low impact fracture related to osteopenia within two years of baseline visit

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00790101

Layout table for location information
United States, New Jersey
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Layout table for investigator information
Study Director: Tara Semanchik Sanofi
Layout table for additonal information
Responsible Party: Medical Affairs Study Director, Sanofi-Aventis Identifier: NCT00790101    
Other Study ID Numbers: HMR4003B_4033
First Posted: November 13, 2008    Key Record Dates
Last Update Posted: January 11, 2011
Last Verified: January 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Risedronic Acid
Raloxifene Hydrochloride
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators